Enorama Pharma AB (ERMA) — Working Capital to Net Assets Ratio
Enorama Pharma AB (ERMA) has a Working Capital to Net Assets ratio of 34.4% as of March 2026. Working capital of Skr-12.60 Million (current assets of Skr22.77 Million minus current liabilities of Skr35.37 Million) is measured against net assets of Skr-36.63 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See financial flexibility index of Enorama Pharma AB to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Enorama Pharma AB Working Capital to Net Assets (2014–2025)
This chart shows how Enorama Pharma AB's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2014 to 2025. As of March 2026, the ratio stands at 34.4%, reflecting working capital of Skr-12.60 Million against net assets of Skr-36.63 Million SEK. See ERMA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Enorama Pharma AB (2014–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Enorama Pharma AB from 2014 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Enorama Pharma AB (ERMA) market capitalisation.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 101.1% | Skr-23.72 Million | Skr-23.45 Million | Skr8.00 Million | Skr31.71 Million | ▲ +10.5 pp |
| 2024 | 90.6% | Skr7.07 Million | Skr7.80 Million | Skr15.16 Million | Skr8.09 Million | ▲ +76.5 pp |
| 2023 | 14.1% | Skr2.75 Million | Skr19.54 Million | Skr12.96 Million | Skr10.22 Million | ▲ +16.2 pp |
| 2022 | -2.1% | Skr-674.00K | Skr31.52 Million | Skr11.75 Million | Skr12.43 Million | ▼ -52.4 pp |
| 2021 | 50.3% | Skr10.73 Million | Skr21.35 Million | Skr22.41 Million | Skr11.68 Million | ▲ +376.0 pp |
| 2020 | -325.8% | Skr-5.79 Million | Skr1.78 Million | Skr12.82 Million | Skr18.61 Million | ▼ -431.8 pp |
| 2019 | 106.0% | Skr7.61 Million | Skr7.18 Million | Skr18.02 Million | Skr10.40 Million | ▲ +85.0 pp |
| 2018 | 21.0% | Skr3.57 Million | Skr17.02 Million | Skr18.28 Million | Skr14.71 Million | ▲ +61.4 pp |
| 2017 | -40.4% | Skr-2.98 Million | Skr7.36 Million | Skr2.10 Million | Skr5.08 Million | ▼ -71.6 pp |
| 2016 | 31.1% | Skr2.83 Million | Skr9.08 Million | Skr3.97 Million | Skr1.15 Million | ▲ +46.5 pp |
| 2015 | -15.4% | Skr-1.00 Million | Skr6.52 Million | Skr1.09 Million | Skr2.09 Million | ▲ +5.6 pp |
| 2014 | -21.0% | Skr-558.00K | Skr2.66 Million | Skr26.00K | Skr584.00K | — |